Iressa

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
The aim of this study was to evaluate the usefulness of EGFR mutation status in serum DNA as a means of predicting a benefit from… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
Highly Cited
2004
Highly Cited
2004
On May 5, 2003, gefitinib (Iressa; ZD1839) 250-mg tablets (AstraZeneca Inc.) received accelerated approval by the United States… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2003
Highly Cited
2003
On May 5, 2003, gefitinib (Iressa), ZD1839) 250-mg tablets received accelerated approval by the U.S. Food and Drug Administration… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
The epidermal growth factor receptor (EGFR) is a promising target for anticancer therapy because of its role in tumor growth… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Epidermal growth factor receptor (EGFR) tyrosine kinase is a potential target for anticancer therapy. ZD1839 (Iressa) is a… (More)
  • figure 3
  • figure 1
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2001
Highly Cited
2001
The transforming growth factor-alpha/epidermal growth factor receptor (TGF-alpha-EGFR) autocrine pathway, which is involved in… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Review
2001
Review
2001
Several epithelial tumors display epidermal growth factor receptor (EGFR) overexpression (with or without EGFR gene amplification… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Transforming growth factor alpha (TGF-alpha) is an autocrine growth factor for human cancer. Overexpression of TGF-alpha and its… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2000
Highly Cited
2000
The blockade of epidermal growth factor receptor (EGFR) function with monoclonal antibodies has major antiproliferative effects… (More)
  • table 1
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
Review
2000
Review
2000
ZD1839 ('Iressa') is an orally active, selective epidermal growth factor receptor-tyrosine kinase inhibitor which blocks signal… (More)
Is this relevant?